Ryan Robinson
Director of Finance/CFO at Tourmaline Bio, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Sandeep Kulkarni | M | 43 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | 3 years |
Ram Aiyar | M | - |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | 4 years |
Caley Castelein | M | 53 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | 2 years |
W. Middlekauff | M | 63 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | 2 years |
Clay Siegall | M | 63 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | 1 years |
Aaron Kantoff | M | 29 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | 2 years |
Susan Jones | M | 64 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | 2 years |
Kevin Johnson | M | 60 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | 1 years |
Parvinder Singh Thiara | M | 39 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | 2 years |
Tim Anderson | M | - |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | - |
Steve Colletti | M | - |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | 1 years |
Gerhard Hagn | M | - | - | |
Mark McDade | M | 69 | 1 years | |
Colin Walsh | M | 38 |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | 4 years |
Yung H. Chyung | M | 48 | 1 years | |
Rebecca Luse | F | - |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | - |
Sapna R. Srivastava | M | 53 | 1 years | |
Vineet Agarwal | M | - |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Cariad Chester | M | - |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | - |
Christian Schubert | M | - |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 16 | 80.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ryan Robinson
- Personal Network